

Independent Auditor's Report

To the Members of **Biocon Pharma Limited**
Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Biocon Pharma Limited (the "Company") which comprise the balance sheet as at 31 March 2026, and the statement of profit and loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, and its loss and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's directors' report, but does not include the financial statements and auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's and Board of Directors Responsibilities for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of

affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Independent Auditor's Report (continued...)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. A. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - c. The balance sheet, the statement of profit and loss (including other comprehensive income), the statement of changes in equity and the statement of cash flows dealt with by this Report are in agreement with the books of account.

- d. In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e. On the basis of the written representations received from the directors as on 31 March 2026 and 01 April 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164(2) of the Act.
 - f. The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3) (b) and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a. The Company does not have any pending litigations which would impact its financial position.
 - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - d. (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 36 to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 36 to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities

Independent Auditor's Report (continued...)

identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.
- e. The Company has neither declared nor paid any dividend during the year.
- f. Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except that the audit trail was not enabled (i) at the application level for certain fields / tables relating to all the significant processes and (ii) for certain changes at the application level which were performed by users having privileged access rights. Further, where audit trail (edit log) facility was

enabled and operated, we did not come across any instance of audit trail feature being tampered with. Additionally, except where the audit trail was not enabled, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

- C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the Company has not paid any remuneration to its directors during the year. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sanjay Sharma

Partner

Membership No.: 063980

ICAI UDIN:26063980JPBKSD9572

Place: Bengaluru

Date: 07 May 2026

Annexure A to the Independent Auditor's Report on the Financial Statements of Biocon Pharma limited for the year ended 31 March 2026

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

- | | |
|--|---|
| <p>(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.</p> <p>(B) The Company has maintained proper records showing full particulars of intangible assets.</p> <p>(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.</p> <p>(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the Company.</p> <p>(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.</p> <p>(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.</p> <p>(ii) (i) (a) The inventory, except stocks lying with third parties, has been physically verified by the management during the year. For stocks lying with third parties at the year-end, written confirmations have been obtained. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory</p> <p>(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned any working capital limits in excess of five crore rupees in aggregate from banks and financial institutions on the basis of security of current assets at any point of time of the year. Accordingly, clause 3(iii)(b) of the Order is not applicable to the Company.</p> <p>(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loans or</p> | <p>advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. The Company has made investment in other parties. The Company has not made any investments in companies, firms and limited liability partnership. Accordingly, provisions of clauses 3(iii)(a), 3(iii) (c) to 3(iii) (f) of the Order are not applicable to the Company.</p> <p>(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made are not prejudicial to the interest of the Company.</p> <p>(iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 and 186 of the Companies Act, 2013 ("the Act"). In respect of the investments made by the Company, in our opinion the provisions of Section 186 of the Act have been complied with.</p> <p>(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.</p> <p>(vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its manufactured goods and services provided by it and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.</p> <p>(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.</p> <p>According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities. The Company did not have any dues under Employees State Insurance.</p> <p>According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2026 for a period of more than six months from the date they became payable.</p> <p>(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax which have not been deposited on account of any dispute are as follows:</p> |
|--|---|

Annexure A to the Independent Auditor's Report on the Financial Statements of
Biocon Pharma Limited for the year ended 31 March 2026 (Continued...)

Name of the statute	Nature of the dues	Amount (Rs. in million)	under protest (Rs. in million)	Period to which the amount relates	Forum where dispute is pending
Goods and Service Tax Act, 2017	GST	9.28	0.07	FY 2021-22	Joint Commissioners (Appeals)

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.
- (ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) In our opinion and according to the information and explanations given to us by the management, the Company has not obtained any term loans. Accordingly, clause 3(ix)(c) of the Order is not applicable.
- (d) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Act. The Company does not hold any investments in any associates or joint ventures.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under the Act).
- (x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- (xiii) The Company is an unlisted public company and a wholly owned subsidiary of a listed public company and accordingly, exempted from constitution of an 'audit committee' as stipulated under Section 177 of the Act read with Rule 4(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014. In our opinion and according to the information and explanations given to us and on the basis of our examination of records of the Company, transactions with the related parties are in compliance with Section 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports of the Company issued till date for the period under audit.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) The Company is not part of any group (as defined in the regulations made by the Reserve Bank of India). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- (xvii) The Company has incurred cash losses of Rs 875 million in the current financial year; however, no cash loss was incurred in the previous financial year.

Annexure A to the Independent Auditor's Report on the Financial Statements of
Biocon Pharma Limited for the year ended 31 March 2026 (Continued...)

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sanjay Sharma

Partner

Membership No.: 063980

ICAI UDIN:26063980JPBKSD9572

Place: Bengaluru

Date: : 07 May 2026

Annexure B to the Independent Auditor's Report

on the financial statements of Biocon Pharma Limited for the year ended 31 March 2026

Report on the internal financial controls with reference to the aforesaid financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Biocon Pharma Limited ("the Company") as of 31 March 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2026, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing

and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sanjay Sharma

Partner

Membership No.: 063980

ICAI UDIN:26063980JPBKSD9572

Place: Bengaluru

Date: 07 May 2026

Standalone Balance Sheet

as at March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Particulars	Note	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Property, plant and equipment	3	2,659	2,812
Capital work-in-progress	3	283	157
Right-of-use assets	4(a)	33	47
Other Intangible assets	4(b)	9	31
Intangible assets under development	4(b)	457	359
Financial assets			
(i) Investments	5(a)	2,069	2,069
Deferred tax Asset (net)	26(d)	568	280
Other tax assets (net)		123	95
Other non-current assets	7(a)	192	24
Total non-current assets		6,393	5,874
Current assets			
Inventories	8	2,847	2,662
Financial assets			
(i) Investments	5(b)	1,157	-
(ii) Trade receivables	9	6,286	6,518
(iii) Cash and cash equivalents	10	304	218
(iv) Other financial assets	6(a)	103	54
Other current assets	7(b)	538	711
Total current assets		11,235	10,163
TOTAL ASSETS		17,628	16,037
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11(a)	141	141
Other equity	11(b)	(211)	676
Total equity		(70)	817
Liabilities			
Non-current liabilities			
Financial liabilities			
(i) Lease liabilities	30	18	36
Provisions	13(a)	64	34
Other non current liabilities	16(a)	411	408
Total non-current liabilities		493	478
Current liabilities			
Financial liabilities			
(i) Borrowing	12(b)	12,012	8,862
(ii) Lease liabilities	30	18	14
(iii) Trade payables	14		
(a) Total outstanding dues of micro enterprises and small enterprises ; and		60	81
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		4,821	5,527
(iv) Other financial liabilities	15(a)	147	109
Other current liabilities	16(b)	60	74
Provisions	13(b)	53	44
Current tax liabilities (net)		34	31
Total current liabilities		17,205	14,742
TOTAL LIABILITIES		17,698	15,220
TOTAL EQUITY AND LIABILITIES		17,628	16,037

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number.: 101248W/W-100022

for **and on behalf of the Board of Directors of Biocon Pharma Limited****Sanjay Sharma**

Partner

Membership No.: 063980

Kiran Mazumdar-Shaw

Director

DIN: 00347229

Shreehas Pradeep Tambe

Director

DIN: 09796480

Neel Kanth Chandgothia

Chief Financial Officer

Anil Kumar Panchariya

Company Secretary

Membership No.: F10956

Bengaluru

May 07, 2026

Bengaluru

May 07, 2026



Statement of Profit and Loss

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Particulars	Note	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	17	8,220	9,701
Other income	18	492	124
Total income		8,712	9,825
Expenses			
Cost of materials consumed	19	4,274	4,967
Purchases of stock-in-trade		1,969	1,099
Changes in inventories of Stock-in-trade, finished goods and work-in-progress	20	(493)	(692)
Employee benefits expense	21	834	792
Finance cost	22	43	7
Depreciation and amortisation expense	23	366	361
Other expenses	24	2,836	2,287
Total expenses		9,829	8,821
Profit before tax and exceptional item		(1,117)	1,004
Exceptional items, net	38	(53)	-
(Loss)/Profit before tax		(1,170)	1,004
Tax expense			
Current tax	26		160
Deferred tax	26	(288)	176
MAT credit utilised/(entitlement)		-	(155)
Other deferred tax (credit)/charge		-	-
Total tax expense		(288)	181
(Loss)/Profit for the year		(882)	823
Other comprehensive income			
(i) Items that will be not be reclassified subsequently to profit or loss			
Re-measurement on defined benefit plans		(6)	(4)
Income tax effect		1	1
Effective portion of gains/(losses) on hedging instrument in cash flow hedges		-	(1)
Income tax effect		-	-
		-	(1)
Other comprehensive income/(loss) for the year, net of taxes		(5)	(4)
Total comprehensive income for the year, net of taxes		(887)	819
Earnings / (loss) per equity share			
Basic (in Rs.)	32	(62.56)	58.39
Diluted (in Rs.)	32	(62.56)	0.93

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number.: 101248W/W-100022

Sanjay Sharma

Partner

Membership No.: 063980

Bengaluru

May 07, 2026

for and on behalf of the Board of Directors of Biocon Pharma Limited

Kiran Mazumdar-Shaw

Director

DIN: 00347229

Neel Kanth Chandgothia

Chief Financial Officer

Bengaluru

May 07, 2026

Shreehas Pradeep Tambe

Director

DIN: 09796480

Anil Kumar Panchariya

Company Secretary

Membership No.: F10956

Statement of Changes in Equity

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

A. Equity share capital

Particulars	March 31, 2026	March 31, 2025
Opening balance	141	141
Issue of equity share capital	-	-
Closing balance	141	141

B. Other equity

Particulars	Reserves and surplus	Items of Other Comprehensive Income		Shares pending for allotment	Total other equity
	Retained earnings	Cash flow hedging reserve	Other items of other comprehensive income		
Balance as at April 01, 2024	(156)	-	(1)	1	(156)
Cashflow hedge reserve reclassification adjustment	-	-	-	(1)	-
Profit for the year	823	-	-	-	823
Other comprehensive income / (loss)	-	(1)	(3)	-	(4)
Other adjustment	13	-	-	-	13
Total comprehensive income / (expense) for the year	836	(1)	(3)	(1)	832
Balance as at March 31, 2025	680	(1)	(4)	-	676
Cashflow hedge reserve reclassification adjustment	-	-	-	-	-
Profit for the year	(882)	-	-	-	(882)
Other comprehensive income / (loss)	-	-	(5)	-	(5)
Other adjustment	-	-	-	-	-
Total comprehensive income / (expense) for the year	(882)	-	(5)	-	(887)
Balance as at March 31, 2026	(202)	(1)	(9)	-	(211)

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number.: 101248W/W-100022

for and on behalf of the Board of Directors of Biocon Pharma Limited

Sanjay Sharma

Partner

Membership No.: 063980

Kiran Mazumdar-Shaw

Director

DIN: 00347229

Shreehas Pradeep Tambe

Director

DIN: 09796480

Neel Kanth Chandgothia

Chief Financial Officer

Anil Kumar Panchariya

Company Secretary

Membership No.: F10956

Bengaluru

May 07, 2026

Bengaluru

May 07, 2026

Statement of Cash Flows

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit/(Loss) for the year	(882)	823
Adjustments to reconcile profit/ loss for the year to net cash flows		
Unrealised foreign exchange gain	(289)	26
Depreciation and amortisation expense	366	361
Net gain on sale of current investment	(5)	(18)
Provision for doubtful debts, (net)	169	(83)
Interest Expense	43	7
Net gain on financial assets measured at fair value through profit or loss	(4)	(3)
Tax expense	(288)	181
Operating profit before changes in operating assets and liabilities	(890)	1,294
Working capital adjustments		
(Increase)/decrease in inventories	(185)	(1,406)
(Increase)/decrease in trade receivables	421	(1,435)
(Increase)/decrease in other assets	15	(89)
Increase/(decrease) in trade payable, other liabilities and provisions	(796)	571
Cash used in operations	(1,435)	(1,065)
Direct taxes paid, (net of refunds)	(25)	(218)
Net cash used in operating activities	(1,460)	(1,283)
II Cash flows from investing activities		
Purchase of property, plant and equipment	(320)	(249)
Purchase of intangible assets (including under development)	(98)	(75)
Recovery of loans from subsidiaries	-	208
Purchase of investments	(4,210)	-
Proceeds from sale of investments	3,062	128
Proceeds from maturity of bank deposits and inter corporate deposits	-	752
Net cash flow from /(used in) investing activities	(1,566)	764
III Cash flows from financing activities		
Proceeds from issue of convertible redeemable non cumulative preference shares	2,000	-
Proceeds from short term borrowings	1,150	-
Repayment of lease liabilities	(18)	(25)
Interest paid	(39)	-
Net cash flow generated (used in)/from financing activities	3,093	(25)
IV Net (decrease)/increase in cash and cash equivalents (I + II + III)	67	(544)
V Effect of exchange differences on cash and cash equivalents held in foreign currency	19	12
VI Cash and cash equivalents at the beginning of the year	218	750
VII Cash and cash equivalents at the end of the year (IV + V + VI)	304	218
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents (Note 10)		
Balances with banks - on current accounts	304	218
	304	218
Balance as per statement of cash flows	304	218

Statement of Cash Flows

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Reconciliation between opening and closing balance sheet for liabilities arising from financing activities as March 31, 2026

Particulars	Opening balance April 01, 2025	Cash flows	Non-cash movement	Closing balance March 31, 2026
Borrowings (including current maturities)	8,862	-	3,150	12,012
Lease liabilities (including current)	50	(18)	4	36
	8,912	(18)	3,154	12,048

Reconciliation between opening and closing balance sheet for liabilities arising from financing activities as at March 31, 2025

Particulars	Opening balance April 01, 2024	Cash flows	Non-cash movement	Closing balance March 31, 2025
Borrowings (including current maturities)	8,862	-	-	8,862
Lease liabilities (including current)	10	(25)	65	50
	8,872	(25)	65	8,912

(a) Statement of Cash Flows has been prepared under the indirect method as set out in the Ind AS 7 "Statement of Cash Flows".

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number: 101248W/W-100022

for **and on behalf of the Board of Directors of Biocon Pharma Limited****Sanjay Sharma**

Partner

Membership No.: 063980

Kiran Mazumdar-Shaw

Director

DIN: 00347229

Shreehas Pradeep Tambe

Director

DIN: 09796480

Neel Kanth Chandgothia

Chief Financial Officer

Anil Kumar Panchariya

Company Secretary

Membership No.: F10956

Bengaluru

May 07, 2026

Bengaluru

May 07, 2026

Notes to financial statements

for the year ended March 31, 2026

1. Company Overview

1.1 Reporting entity

Biocon Pharma Limited ("the Company") was incorporated in India on October 31, 2014, as a wholly owned subsidiary of Biocon Limited. The Company is a public limited company incorporated and domiciled in India and has its registered office in Bengaluru, Karnataka. 20KM Electronics City, Hosur Road Bangalore - 560100, Bangalore, Karnataka, India - 560100. The Corporate Identification Number of Company is U24232KA2014PLC077036. The Company has setup its formulations manufacturing facility for oral solid dosages at Biocon SEZ, Bengaluru and commenced its commercial production on March 23, 2020.

1.2 Basis of preparation of financial statements

a) Statement of compliance

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of Companies Act, 2013, (the 'Act') and other relevant provisions of the Act.

The Company has net current liability position of Rs. 5,970 million as at March 31, 2026 (March 31, 2025: Rs. 4,579 million), current year loss of Rs. 882 million (March 31, 2025 profit of Rs. 823 million) and negative networth of Rs. 70 million (March 31, 2025 positive Rs. 817 million). Notwithstanding the current liability position, current year loss and negative networth, the management of the Company believes that the Company will be able to continue to operate as a going concern for the foreseeable future and meet all its liabilities as they fall due for payment based on its future cash flow projections and continued financial support from Biocon Limited, "the Holding Company". The Holding Company undertakes to provide sufficient financial and other support to the Company for a foreseeable future and not to call for settlement of any amounts that the Company owes to it. Accordingly, these financial statements have been prepared under the going concern assumption. These financial statements are approved and authorised for issuance by the Company's Board of Directors on May 07, 2026.

Details of the Company's material accounting policies are included in Note 2.

b) Functional and presentation currency

These financial statements are presented in Indian rupees (INR), which is also the functional currency of the Company. All amounts have been rounded-off to the nearest million, unless otherwise indicated.

c) Basis of measurement

These financial statements have been prepared on the historical cost basis, except for the following items:

- Certain financial assets and liabilities are measured at fair value;

- Derivative Financial Instruments at fair value; and
- Net defined benefit assets/(liability) are measured at fair value of plan assets, less present value of defined benefit obligations.

d) Use of estimates and judgements

The preparation of the financial statements in conformity with Ind AS requires Management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

Judgements

Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognized in the financial statements is included in the following notes:

- Note 2(a) and Note 28 — Financial instruments
- Note 2(b), 2(c) — Useful lives of property, plant and equipment and intangible assets
- Note 2(g) and Note 27 — measurement of defined benefit obligation; key actuarial assumptions;
- Note 2(g) and Note 34 — Share based payments
- Note 2(k) and 26 — Provision for income taxes and related tax contingencies and Evaluation of recoverability of deferred tax assets
- Note 2(i) and 17 — Revenue Recognition: whether revenue from sale of product is recognised over time or at a point in time

1.3 Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment for the year ended March 31, 2026 is included in the following notes:

- Note 2(f)(ii) — impairment test of non-financial assets; key assumptions underlying recoverable amounts;
- Note 26 — recognition of deferred tax assets: availability of future taxable profit against which tax losses carried forward can be used;

Notes to financial statements

for the year ended March 31, 2026

- Note 27 – measurement of defined benefit obligation; key actuarial assumptions.
- Note 13(a), 13(b) and 32 – recognition and measurement of provisions, contingencies and commitments: key assumptions about the likelihood and magnitude of an outflow of resources;

1.4 Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in following notes

- Note 34 – Share based payments
- Note 2(a) and 28 – Financial Instruments

2. Material accounting policies

a. Financial instruments

i. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

Trade receivables generally do not contain any significant financing component requiring separation and are therefore recognized initially at the transaction price determined as per Ind AS 115 "Revenue from Contracts with Customers".

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as measured at

- Amortised cost;
- Fair value through other comprehensive income (FVOCI) – equity investment; or
- Fair value through profit or loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment by investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Equity investments

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS 103 applies are classified as at FVPL. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable. If the Company

Notes to financial statements

for the year ended March 31, 2026

decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the Statement of Profit and Loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss to retained earnings. Equity instruments included within the FVPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

Investments in subsidiaries

Equity investments in subsidiaries are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiaries, the difference between net disposal proceeds and the carrying amounts are recognised in the Statement of Profit and Loss.

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in statement of profit and loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in statement of profit and loss. Any gain or loss on derecognition is recognised in statement of profit and loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in statement of profit and loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to statement of profit and loss.

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in statement of profit and loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in statement of profit

and loss. Any gain or loss on derecognition is also recognised in statement of profit and loss.

iii. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire.

The Company also derecognizes a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in statement of profit and loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

v. Convertible Preference shares

Convertible preference shares are separated into liability and equity components based on the terms of the contract. On issuance of the convertible preference shares, the fair value of the liability component is determined using a market rate for an equivalent non-convertible instrument. This amount is

Notes to financial statements

for the year ended March 31, 2026

classified as a financial liability measured at amortised cost (net of transaction costs) until it is extinguished on conversion or redemption.

The remainder of the proceeds is allocated to the conversion option that is recognised and included in equity since conversion option meets Ind AS 32 criteria for fixed to fixed classification. Transaction costs are deducted from equity, net of associated income tax. The carrying amount of the conversion option is not remeasured in subsequent years.

Transaction costs are apportioned between the liability and equity components of the convertible preference shares based on the allocation of proceeds to the liability and equity components when the instruments are initially recognised.

vi. Derivative financial instruments and hedge accounting

The Company holds derivative financial instruments to hedge interest rate risk exposures. Embedded derivatives are separated from the host contract and accounted for separately if the host contract is not a financial asset and certain criteria are met.

Derivatives are initially measured at fair value. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are generally recognised in statement of profit and loss.

The Company designates certain derivatives as hedging instruments to hedge the variability in cash flows associated with highly probable forecast transactions arising from changes in foreign exchange rates and interest rates.

At inception of designated hedging relationships, the Company documents the risk management objective and strategy for undertaking the hedge. The Company also documents the economic relationship between the hedged item and the hedging instrument, including whether the changes in cash flows of the hedged item and hedging instrument are expected to offset each other.

Cash flow hedges

When a derivative is designated as a cash flow hedging instrument, the effective portion of changes in the fair value of the derivative is recognised in OCI and accumulated in other equity under 'effective portion of cash flow hedges'. The effective portion of changes in the fair value of the derivative that is recognised in OCI is limited to the cumulative change in fair value of the hedged item, determined on a present value basis, from inception of the hedge. Any ineffective portion of changes in the fair value of the derivative is recognised immediately in statement of profit and loss.

If a hedge no longer meets the criteria for hedge accounting or the hedging instrument is sold, expires, is terminated or is exercised, then hedge accounting is discontinued prospectively. When hedge accounting for cash flow hedges is discontinued, the amount that has been accumulated in other equity remains there until, for a hedge of a transaction resulting in recognition

of a non-financial item, it is included in the non-financial item's cost on its initial recognition or, for other cash flow hedges, it is reclassified to profit or loss in the same period or periods as the hedged expected future cash flows affect profit or loss.

If the hedged future cash flows are no longer expected to occur, then the amounts that have been accumulated in other equity are immediately reclassified to statement of profit and loss.

vii. Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

b. Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. The cost of property, plant and equipment including self-constructed items, comprises the cost of materials and direct labor, any other costs including import duty and non refundable taxes or levies, any other costs that are directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Expenditure incurred on startup and commissioning of the project and/or substantial expansion, including the expenditure incurred on trial runs (net of trial run receipts, if any) up to the date of commencement of commercial production are capitalised.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in statement of profit and loss.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

Advances paid towards acquisition of property, plant and equipment outstanding at each Balance Sheet date, are shown under other non-current assets and cost of assets not ready for intended use before the year end, are shown as capital work-in-progress.

ii. Depreciation

Depreciation is calculated on cost of items of property, plant and equipment less their estimated residual values over their estimated useful lives using the straight-line method. Assets

Notes to financial statements

for the year ended March 31, 2026

acquired under finance leases are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term.

Asset	Management estimate of useful life	Useful life as per Schedule II
Building	30 years	30 years
Plant and equipment (including Electrical installation and Lab equipment)	12 -15 years	8-20 years
Computers and servers	3 years	3-6 years
Furniture and fixtures	6 years	10 years

The estimated useful lives of items of property, plant and equipment for the current and comparative periods are as follows:

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate. Based on technical evaluation and consequent advice, the management believes that its estimates of useful lives as given above best represent the period over which management expects to use these assets.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of).

c. Intangible assets

Others

Other intangible assets are initially measured at cost. Subsequently, such intangible assets are measured at cost less accumulated amortisation and any accumulated impairment losses.

i. Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in statement of profit and loss as incurred and cost can be measured reliably.

ii. Amortisation

Intangible assets are amortised on a straight line basis over the estimated useful life as follows:

— Computer software	3-5 years
— Marketing and Manufacturing rights	5-10 years

Amortisation method, useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate.

d. Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the first-in first-out formula, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their present location and condition. In the case of manufactured inventories and work-in-progress, cost includes an appropriate share of fixed production overheads based on normal operating capacity.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

Raw materials, components and other supplies held for use in the production of finished products are not written down below cost except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value.

The comparison of cost and net realisable value is made on an item-by-item basis.

e. Foreign currency Transactions and translations:

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at balance sheet date exchange rates are generally recognised in Statement of Profit and Loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example translation differences on non-monetary assets such as equity investments classified as FVOCI are recognised in other comprehensive income (OCI).

f. Impairment

i. Impairment of financial assets

In accordance with Ind AS 109 Financial Instruments, the Company applies expected credit loss ("ECL") model for measurement and recognition of impairment loss on following:

— financial assets measured at amortised cost; and

Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime expected credit losses. For all other financial assets, ECL are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL.

Notes to financial statements

for the year ended March 31, 2026

Loss allowance for financial assets measured at amortised cost are deducted from gross carrying amount of the assets.

ii. Impairment of non-financial assets

The Company assess at each reporting date whether there is any indication that the carrying amount may not be recoverable. If any such indication exists, then the asset's recoverable amount is estimated and an impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount in the statement of profit and loss.

The recoverable amount of a CGU (or an individual asset) is higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flow, discounted to their present value using a pre-tax discount rate that reflects current market assessment of the time value of money and the risks specific to CGU (or the asset).

The Company's non-financial assets inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating unit (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or groups of CGUs) on a pro rata basis. Impairment losses are recognized in statement of profit and loss.

An impairment loss in respect of assets which has been recognised in prior periods, the Company reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

g. Employee benefits

i. Short-term employee benefits:

All employee benefits falling due within twelve months from the end of the period in which the employees render the related services are classified as short-term employee benefits, which include benefits like salaries, wages, short term compensated absences, performance incentives, etc. and are recognised as expenses in the period in which

the employee renders the related service and measured accordingly.

ii. Post-employment benefits:

Post-employment benefit plans are classified into defined benefits plans and defined contribution plans as under:

Defined Contribution plans – Gratuity:

The Company provides for gratuity, a defined benefit plan ("the Gratuity Plan") covering the eligible employees of the Company. The Gratuity Plan provides a lump-sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of the employment with the Company.

Liability with regard to the Gratuity Plan are determined by actuarial valuation, performed by an independent actuary, at each balance sheet date using the projected unit credit method. The defined benefit plan is administered by a trust formed for this purpose through the Company gratuity scheme.

The Company recognises the net obligation of a defined benefit plan as a liability in its balance sheet. Gains or losses through re-measurement of the net defined benefit liability are recognised in other comprehensive income and are not reclassified to profit and loss in the subsequent periods. The actual return of the portfolio of plan assets, in excess of the yields computed by applying the discount rate used to measure the defined benefit obligation is recognised in other comprehensive income. The effect of any plan amendments are recognised in the statement of profit and loss.

Defined Contribution plans – Provident Fund:

Eligible employees of the Company receive benefits from provident fund, which is a defined contribution plan. Both the eligible employees and the Company make monthly contributions to the Government administered provident fund scheme equal to a specified percentage of the eligible employee's salary. Amounts collected under the provident fund plan are deposited with in a government administered provident fund. The Company has no further obligation to the plan beyond its monthly contributions.

Defined Contribution plans – Other funds

The Company's contributions to other funds are charged to the consolidated statement of profit and loss as and when the services are received from the employees.

iii. Compensated absences

The Company has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by

Notes to financial statements

for the year ended March 31, 2026

an independent actuary at each balance sheet date using the projected unit credit method on the additional amount expected to be paid/availed as a result of the unused entitlement that has accumulated at the balance sheet date. Expense on non-accumulating compensated absences is recognised in the period in which the absence occur. The obligations are presented as current liabilities in the Balance sheet if the Company does not have an unconditional right to defer the settlement for at least twelve months after the reporting date.

The liability in respect of all defined benefit plans and other long term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

Remeasurement gains and losses on other long term benefits are recognised in the Statement of Profit and Loss in the year in which they arise. Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are included in other equity in the Statement of Changes in Equity and in the Balance Sheet. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs. Any differential between the plan assets (for a funded defined benefit plan) and the defined benefit obligation as per actuarial valuation is recognised as a liability if it is a deficit or as an asset if it is a surplus (to the extent of the lower of present value of any economic benefits available in the form of refunds from the plan or reduction in future contribution to the plan).

Past service cost is recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced).

iv. Share-based compensation

The grant date fair value of equity settled share-based payment awards granted to employees is recognised as an

employee expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognised as expense is based on the estimate of the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that do meet the related service and non-market vesting conditions at the vesting date.

h. Provisions (other than for employee benefits)

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows (representing the best estimate of the expenditure required to settle the present obligation at the balance sheet date) at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost. Expected future operating losses are not provided for.

Onerous contracts

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

i. Revenue from contracts with customers

i. Sale of goods

Revenue is recognised when a promise in a customer contract (performance obligation) has been satisfied by transferring control over the promised goods to the customer. Control over a promised goods refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, those goods. Control is usually transferred upon shipment, delivery to, upon receipt of goods by the customer, in accordance with the delivery and acceptance terms agreed with the customers. However, in certain cases, revenue is recognized on sale of products where shipment is on hold at specific request of the customer provided performance obligation conditions

Notes to financial statements

for the year ended March 31, 2026

has been satisfied and control is transferred, with customer taking title of the goods. The amount of revenue to be recognised (transaction price) is based on the consideration expected to be received in exchange for goods, excluding amounts collected on behalf of third parties such as goods and service tax or other taxes directly linked to sales. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on their relative stand-alone selling prices. Revenue from product sales are recorded net of allowances for estimated rebates, cash discounts and estimates of product returns, all of which are established at the time of sale.

For contracts with distributors, no sales are recognised when goods are physically transferred to the distributor under a consignment arrangement, or if the distributor acts as an agent. In such cases, sales are recognised when control over the goods transfers to the end-customer, and distributor's commissions are presented within marketing and distribution.

The consideration received by the Company in exchange for its goods may be fixed or variable. Variable consideration is only recognised when it is considered highly probable that a significant revenue reversal will not occur once the underlying uncertainty related to variable consideration is subsequently resolved. Invoices are usually payable within 60-120 days.

ii. Royalty income and profit share

The Royalty income and profit share earned through a License or collaboration partners is recognised as the underlying sales are recorded by the Licensee or collaboration partners.

iii. Sales Return Allowances

The Company accounts for sales return by recording an allowance for sales return concurrent with the recognition of revenue at the time of a product sale. The allowance is based on Company's estimate of expected sales returns. The estimate of sales return is determined primarily by the Company's historical experience in the markets in which the Company operates.

iv. Interest income and expense

Interest income or expense is recognised using the effective interest method.

j. Government grants

The Company recognises government grants at their fair value only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Government grants received in relation to assets are recognised as deferred income and amortised over the useful life of such asset. Government grants, which are revenue in nature

are either recognised as income or deducted in reporting the related expense based on the terms of the grant, as applicable.

k. Income taxes

Income tax comprises current and deferred income tax. Income tax expense is recognised in statement of profit and loss except to the extent that it relates to an item recognised directly in equity in which case it is recognised in other comprehensive income. Current income tax for current year and prior periods is recognised at the amount expected to be paid or recovered from the tax authorities, using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes.

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred income tax assets and liabilities are recognised for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements except when:

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss at the time of transaction;
- temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred income tax assets and liabilities are measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognised as income or expense in the period that includes the enactment or substantive enactment date. A deferred income tax assets is

Notes to financial statements

for the year ended March 31, 2026

recognised to the extent it is probable that future taxable income will be available against which the deductible temporary timing differences and tax losses can be utilised. The Company offsets income-tax assets and liabilities, where it has a legally enforceable right to set off the recognised amounts and where it intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

l. Borrowing cost

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred.

m. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period adjusted for treasury shares held. Diluted earnings per share is computed using the weighted-average number of equity and dilutive equivalent shares outstanding during the period, except where the results would be anti-dilutive.

n. Operating cycle

The Company classifies an asset as current asset when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it holds the asset primarily for the purpose of trading;
- it expects to realise the asset within twelve months after the reporting period; or
- the asset is cash or a cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when –

- it expects to settle the liability, or consume it, in its normal operating cycle;
- it holds the liability primarily for the purpose of trading;
- the liability is due to be settled within twelve months after the reporting period; or
- it does not have the unconditional right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. The Company normal operating cycle is twelve months.

o. Exceptional items

Exceptional items refer to items of income or expense, including tax items, within the statement of profit and loss which are non-recurring and are of such size, nature or incidence that their separate disclosure is considered necessary to explain the performance of the Company.

p. Equity share capital

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

q. Recent pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. In May 2025, MCA notified amendments to Ind AS 21 - The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Group has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendments to:

1. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 - The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date, and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. Further, the amendment also clarifies the classification of liability that could, at the option of counterparty, result in its settlement by transfer of the entity's own equity instruments. The Company has reassessed the classification of borrowings based on aforesaid amendments and accordingly, certain borrowings, earlier classified as non-current financial liabilities have been reclassified to current financial liabilities. This reclassification has been made retrospectively in accordance with Ind AS 8 – Accounting policies, changes in accounting estimates and errors, and the comparative financial statements as at March 31, 2025 has been reclassified accordingly. Refer Note 12.
2. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments - Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying

Notes to financial statements

for the year ended March 31, 2026

amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

3. Ind AS 12, International Tax Reform – Pillar Two Model Rules applicable immediately - The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The amendments also require companies to provide new disclosures to compensate for potential loss of information

resulting from the relief. Such disclosures are to be provided for annual reporting periods beginning on or after April 1, 2025. The Company has determined that the rules are not applicable as of now.

Amendment issued but not effective (effective from April 01, 2026):

The Ministry of Corporate Affairs (MCA) through notification dated August 13, 2025, notified amendment to Ind AS 1, Presentation of Financial statements. This amendment removes the carve-outs in Ind AS 1 from IAS 1 when there is a breach of a material covenant that transforms the liability from non current to current. The Company will evaluate the requirements and apply these amendments from the effective date. However, presently the Company does not see any material impact on the financial statements.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

3. Property, plant and equipment and Capital work-in-progress

	Buildings	Plant and equipment [Refer note (a)]	Furniture and fixtures	Total	Capital work-in-progress
Gross carrying amount					
At April 01, 2024	854	3,308	14	4,176	60
Additions	9	57	2	68	165
Disposals/transfers*	-	-	-	-	(68)
At March 31, 2025	863	3,365	16	4,244	157
Additions	-	176	1	177	303
Disposals/transfers*	-	-	-	-	(177)
At March 31, 2026	863	3,541	17	4,421	283
Accumulated depreciation					
At April 01, 2024	113	996	5	1,114	-
Depreciation for the year	28	288	2	318	-
At March 31, 2025	141	1,284	7	1,432	-
Depreciation for the year	29	298	3	330	-
At March 31, 2026	170	1,582	10	1,762	-
Net carrying amount					
At March 31, 2025	722	2,081	9	2,812	157
At March 31, 2026	693	1,959	7	2,659	283

* Transfers relate to capitalisation of assets from Capital work-in-progress to Gross block

(a) Plant and equipment include computers and office equipment.

3(a). Capital work in progress ageing Schedule

As at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	277	2	4	-	283
Total	277	2	4	-	283

As at March 31, 2025

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	97	57	4	-	157
Total	97	57	4	-	157

(i) There are no capital work-in-process whose completion is overdue or has exceeded its cost compared to its original plan as at March 31, 2026 and March 31, 2025.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

4(a) . Right-of-Use-assets

Particulars	Land	Buildings	Total
Gross carrying amount			
At April 01, 2024	18	41	59
Additions	-	57	57
Deletions	-	-	-
At March 31, 2025	18	98	117
Additions	-	-	-
Deletions	-	-	-
At March 31, 2026	18	98	117
Accumulated Depreciation			
At April 01, 2024	10	41	51
Depreciation for the year	2	15	18
Disposals	-	-	-
At March 31, 2025	13	56	69
Depreciation for the year	2	12	14
At March 31, 2026	15	68	83
Net carrying amount			
At March 31, 2025	5	42	47
At March 31, 2026	3	30	34

4 (b). Other Intangible assets and Intangible assets under development

Particulars	Computer software	Marketing and Manufacturing rights	Total	Intangible assets under development
Gross carrying amount				
At April 01, 2024	26	120	146	285
Additions	1	-	1	74
Deletions	-	-	-	-
At March 31, 2025	27	120	147	359
Additions	-	-	-	98
Deletions	0	-	-	-
At March 31, 2026	27	120	147	457
Accumulated amortisation				
At April 01, 2024	14	78	92	-
Amortisation for the year	5	19	24	-
At March 31, 2025	19	97	116	-
Disposals	-	-	-	-
Amortisation for the year	3	19	22	-
At March 31, 2026	22	116	138	-
Net carrying amount				
At March 31, 2025	8	23	31	359
At March 31, 2026	5	4	9	457

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

4 (c). Intangible Asset under Development ageing Schedule

As at March 31, 2026

Particulars	Amount in Intangible Asset under Development for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	93	74	2	287	457
Projects temporarily suspended	-	-	-	-	-
Total	93	-	2	287	457

As at March 31, 2025

Particulars	Amount in Intangible Asset under Development for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	74	2	-	283	359
Projects temporarily suspended	-	-	-	-	-
Total	74	2	-	283	359

- (i) There are no intangible assets under development whose completion is overdue or has exceeded its cost compared to its original plan as at March 31, 2026 and March 31, 2025.
- (ii) The intangible assets under development are subject to various phases of trial run and related approvals. There are no pre-determined completion dates for these assets as these are dependent on obtaining regulatory approvals.

5 (a). Non-current investments

Particulars	March 31, 2026	March 31, 2025
I. Unquoted equity instrument		
In subsidiary company at cost:		
140,000 (March 31, 2025 - 140,000) Equity shares of USD 10 each in Biocon Pharma Inc.	94	94
7,500 (March 31, 2025 - 7,500) Equity shares of USD 1000 each in Biocon Generics Inc	616	616
350,000 (March 31, 2025 - 350,000) Equity shares of GBP 1 each in Biocon Pharma UK Limited	31	31
775,001 (March 31, 2025 - 775,001) Equity shares of EUR 1 each in Biocon Pharma Ireland Limited	68	68
Less: Provision for decline, other than temporary, in the value of non current investments	(63)	(63)
1,200 (March 31, 2025 - 1,200) Equity shares of EUR 1 each in Biocon Pharma Malta Limited	~*	~*
	746	746
II. Unquoted preference instrument		
In subsidiary company at cost :		
1,690,000 (March 31, 2025 - 1,690,000) Preference shares of USD 10 each in Biocon Pharma Inc.	1,173	1,173
1,527,000 (March 31, 2025 - 1,327,000) Preference shares of GBP 1 each in Biocon Pharma UK	150	150
Total non-current investments	2,069	2,069
Aggregate value of unquoted investments	2,069	2,069
Aggregate amount of impairment in the value of investments	63	63

*Amounts are not presented since the amounts are rounded off to Rupees million.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

5 (b). Current investments

Particulars	March 31, 2026	March 31, 2025
Quoted -Investment in mutual funds at fair value through profit or Loss		
Investment in mutual funds	1,157	-
Total quoted -investment in mutual funds	1,157	-
Total current investments	1,157	-
Aggregate book and market value of quoted investments	1,157	-
Aggregate value of unquoted investments	-	-

6. Other financial assets

(a) Current

Particulars	March 31, 2026	March 31, 2025
Interest accrued but not due	24	24
Others	79	30
	103	54

7. Other assets

(a) Non-current

Particulars	March 31, 2026	March 31, 2025
Capital advances	63	4
Balances with statutory / government authorities	114	-
Prepayments	15	20
	192	24

(b) Current

Particulars	March 31, 2026	March 31, 2025
Advance to suppliers	105	157
Balances with statutory / government authorities	299	334
Prepayments	134	220
	538	711

8. Inventories

Particulars	March 31, 2026	March 31, 2025
Raw materials, including goods-in-transit*	816	1,450
Packing materials	353	27
Work-in-progress	1,389	725
Finished goods and stock-in-trade**	289	460
	2,847	2,662

* includes goods in-transit Rs. Nil (March 31, 2025 - Rs. 448)

** the write-downs and reversals are included in changes in inventories of finished goods

Write-down of inventories to net realisable value amounted to Rs. 462 (March 31, 2025 - Rs 359). These were recognised as an expense during the year and included in 'changes in inventories of finished goods and work-in-progress' in the statement of profit and loss.

During the current year the company integrated its generics and biosimilars business and re-assessed its inventory provisioning. The Company accordingly changed its inventory provisioning based on age from date of manufacture to provisioning based on remaining shelf-life of the products. This re-assessment resulted into a release of provision of Rs. 128 during the year ended March 31, 2026 and such debit has been accounted for as a change in estimate within 'Changes in inventories of stock-in-trade, finished goods and work-in-progress' and 'Cost of raw materials' in the statement of profit and loss.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

9. Trade receivables

Particulars	March 31, 2026	March 31, 2025
Break-up for security details:		
(a) Trade Receivables considered good - Unsecured	6,286	6,518
(b) Trade Receivables - credit impaired	204	36
Total trade receivables	6,490	6,554
Less : Allowance for credit loss	204	36
Net trade receivables	6,286	6,518

(i) The Company's exposure to credit and currency risk, and loss allowances are disclosed in Note 28

(ii) Includes receivables from related parties [refer note 25]

(a) Trade receivables Ageing Schedule

As at 31 March 2026

Particulars	Outstanding for following periods from due date of payment							Total
	Unbilled	Not due	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivables - considered good	250	3,385	2,270	204	164	11	2	6,286
Undisputed Trade receivable - credit impaired	-	-	-	68	123	11	2	204
Total	250	3,385	2,270	272	287	22	4	6,490

As at 31 March 2025

Particulars	Outstanding for following periods from due date of payment							Total
	Unbilled	Not due	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivables - considered good	148	4,127	1,745	138	350	10	-	6,518
Undisputed Trade receivable - credit impaired	-	-	29	2	5	-	-	36
Total	148	4,127	1,774	140	355	10	-	6,554

10. Cash and bank balances

Particulars	March 31, 2026	March 31, 2025
Cash and cash equivalents		
Balances with banks:		
On current accounts	304	218
Total cash and cash equivalents	304	218
Total cash and bank balances	304	218

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

11(a). Share capital

Particulars	March 31, 2026	March 31, 2025
Authorised		
20,150,000 (March 31, 2025 - 20,150,000) equity shares of Rs 10 each (March 31, 2025 - Rs. 10 each)	202	202
2,020,000,000 (March 31, 2025 - 1,020,000,000) preference shares of Rs 10 each (March 31, 2025 - Rs. 10 each)	20,200	10,200
Issued, subscribed and fully paid-up		
14,100,000 (March 31, 2025 - 14,100,000) equity shares of Rs 10 each (March 31, 2025 - Rs. 10 each)	141	141
1,073,000,000 (March 31, 2025 - 873,000,000) Optionally convertible redeemable non cumulative preference shares ("OCRPS")	10,730	8,730
	10,871	8,871
Less: Preference share capital classified as financial liability [refer note 12]	(10,730)	(8,730)
	141	141

(i) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

(a) Equity shares	March 31, 2026		March 31, 2025	
	No.	Rs. Million	No.	Rs. Million
At the beginning of the year	14,100,000	141	14,100,000	141
Issued during the year	-	-	-	-
Outstanding at the end of the year	14,100,000	141	14,100,000	141

(b) Optionally convertible redeemable non cumulative preference shares	March 31, 2026		March 31, 2025	
	No.	Rs. Million	No.	Rs. Million
At the beginning of the year	873,000,000	8,730	873,000,000	8,730
Issued during the year	200,000,000	2,000	-	-
Outstanding at the end of the year	1,073,000,000	10,730	873,000,000	8,730

(ii) Terms/ rights attached

(a) Equity shares

The Company has only one class of equity shares having a par value of Rs 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

(b) Optionally Convertible redeemable non cumulative preference shares (OCRPS)

The terms and conditions of "OCRPS" are as below :

- The tenure of the OCRPS shall be 10 years.
- The Company shall have the option to redeem the OCRPS at any time during the tenure of the OCRPS at its face value. The OCRPS shall become redeemable at its face value at the end of the tenure.
- The OCRPS holder shall have the option to convert the OCRPS into equity shares of the Company at any time during the tenure of the OCRPS at a ratio based on fair value or face value of the equity shares as on the date of exercise of the option whichever is higher.
- The holder of the OCRPS shall be entitled to preferential dividend of 3% per annum on the face value of the OCRPS as may be mutually decided between the Company and the OCRPS holder. The dividends are non-cumulative and will be payable subject to availability of profits in the respective financial year and subject to declaration by the Board of Directors of the Company.
- Until redemption of the OCRPS, the OCRPS holder shall have priority of payment of dividend over the equity shareholders.

The aforesaid preference shares are convertible (variable number of equity shares) any time during the tenure of the instrument at the option of the holder. Owing to this feature, the instrument has been classified as financial liability and disclosed at its fair value which is equivalent to the face value. Also refer note 12.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

(iii) Details of shareholders holding more than 5% of each class of shares in the Company:

	March 31, 2026		March 31, 2025	
	No.	Rs. Million	No.	Rs. Million
Equity shares of Rs 10 each fully paid				
Biocon Limited, the Holding Company (including shares held through nominees)	14,100,000	100%	14,100,000	100%
OCRPS of Rs 10 each fully paid				
Biocon Limited, the Holding Company	1,073,000,000	100%	873,000,000	100%

As per records of the Company, including its register of shareholders/ members, the above shareholding represents both legal and beneficial ownerships of shares.

The Company is a wholly owned subsidiary of Biocon limited, hence disclosure for shareholding of promoters has not been disclosed separately.

(iv) During the five years ended 31 March 2026, the Company has not allotted any bonus shares or issued shares for consideration other than cash. No shares have been bought back by the Company.

11(b). Other equity

Particulars	March 31, 2026	March 31, 2025
Retained earnings	(202)	680
Cash flow hedging reserve	(1)	(1)
Other items of other comprehensive income	(9)	(4)
Shares pending for allotment	-	-
	(212)	676

Retained earnings

The amount that can be distributed by the Company as dividends to its equity shareholders.

Cash flow hedging reserve

The cash flow hedging reserve represents the cumulative effective portion of gains or losses (net of taxes, if any) arising on changes in fair value of designated portion of hedging instruments entered into for cash flow hedges.

Other Items of other comprehensive income

Other Items of other comprehensive income represents mark to market gain or loss on financial assets classified as FVTOCI and re-measurements of the defined benefits plan.

12. Borrowings

Particulars	March 31, 2026	March 31, 2025
a) Non Current Borrowings		
Loans from banks (Secured)		
Term loan [Refer Note (a) below]	-	-
Other loans and advances (Unsecured)		
Optionally convertible redeemable non cumulative Preference shares [refer note 11 (a)(ii)(b)]	10,862	8,862
	10,862	8,862
Less: Amount disclosed under the head "Current borrowings" [refer note 12(b)]	(10,862)	(8,862)
	-	-
The above amount includes		
Unsecured borrowings	10,862	8,862
Amount disclosed under the head "current borrowings" [refer note 12(b)]	(10,862)	(8,862)
Net amount	-	-

(a) The Company's exposure to liquidity, interest rate and currency risks are disclosed in note 20.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

12.(b) Current borrowings

Particulars	March 31, 2026	March 31, 2025
Working capital loan - unsecured	1,150	-
Current maturities of long-term borrowings	10,862	8,862
	12,012	8,862

13. Provisions

Particulars	March 31, 2026	March 31, 2025
(a) Non-current		
Provision for employee benefits		
Gratuity [Refer Note 27]	64	34
	64	34
(b) Current		
Provision for employee benefits		
Gratuity [Refer Note 27]	8	4
Compensated absences	47	40
	53	44

(i) Movement in provisions

Particulars	Gratuity	Compensated absences
Balance as at April 01, 2025	38	40
Provision recognised during the year (net)	34	7
Balance as at Mar 31, 2026	72	47
Balance as at April 01, 2024	30	36
Provision recognised during the year (net)	8	3
Balance as at March 31, 2025	38	40

14. Trade payables

Particulars	March 31, 2026	March 31, 2025
Trade payables		
Total outstanding dues of micro and small enterprises (refer note b)	60	81
Total outstanding dues of creditors other than micro and small enterprises	4,821	5,527
	4,881	5,608

(a) Trade payables Ageing Schedule

Particulars	Outstanding for following periods from due date of payment						Total
	Unbilled	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
As at March 31, 2026							
Total outstanding dues of micro enterprises and small enterprises	-	32	28	_*	_*	_*	60
Total outstanding dues of creditors other than micro enterprises and small enterprises	324	1,288	1,565	1,643	-	_*	4,820
	324	1,320	1,593	1,643	-	-	4,880
As at March 31, 2025							
Total outstanding dues of micro enterprises and small enterprises	-	58	23	_*	_*	_*	81
Total outstanding dues of creditors other than micro enterprises and small enterprises	699	1,533	3,047	248	-	_*	5,527
	699	1,591	3,070	248	-	-	5,608

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

(b) Disclosure required under Clause 22 of Micro, Small and Medium Enterprise Development Act, 2006

Particulars	March 31, 2026	March 31, 2025
(i) The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year		
Principal amount due to micro and small enterprises. Interest due on the above	60	81
Interest due on the above		
(ii) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	7	122
(iii) The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	—*	—*
(iv) Interest due and payable for the period of delay in making payment during the year	—	—
(v) The amount of interest accrued and remaining un-paid at the end of each accounting year	—	—
(vi) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of the MSMED Act, 2006	11	4
(a) The above disclosures are provided by the Company based on the information available with the Company in respect of the registration status of its vendors/ suppliers.		
(b) All Trade Payables are 'current'. The Company's exposure to currency and liquidity risks related to trade payables is disclosed in note 28.		

* Amounts are not presented since the amounts are rounded off to Rupees million

15. Other financial liabilities

(a) Current	March 31, 2026	March 31, 2025
Employee benefits payable	48	52
Payables for capital goods	99	58
	147	109

(a) Employee benefit payable was disclosed under trade payable in the previous year. In the current year, the employee payable has been disclosed under other financial liabilities including comparable period.

16. Other liabilities

Particulars	March 31, 2026	March 31, 2025
(a) Non-current		
Deferred revenues	411	408
(b) Current		
Advances from customer	3	4
Statutory taxes and dues payable	22	44
Deferred revenues	35	27
	60	74

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

17. Revenue from operations

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Sale of products		
Finished goods	4,526	3,772
Traded goods	3,437	5,847
Sale of services		
Licensing and development fees	257	34
Other operating revenue		
Incentive from Government [refer note a]	-	48
	8,220	9,701

(a) Pertains to production linked Incentive

17.1 Reconciliation of revenue recognised with contract price

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Reconciliation of revenue recognised with contract price	7,964	9,627
Revenue as per contract price		
Adjustments for : trade discount and prompt pay	(1)	(8)
Total revenue from contract with customers	7,963	9,619

17.2 Disaggregation of revenue from contract with customers

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Timing of revenue recognition		
Products and services transferred at a point in time	7,963	9,619
Products and services transferred over time	257	81
Total revenue from contract with customers	8,220	9,701

17.3 Disaggregated revenue information

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Set out below is the disaggregation of the Company's revenue from contracts with customers:		
Revenues By Geography		
United States of America	5,271	8,651
Mexico	1	266
UK	198	162
Rest of the world	2,611	571
India	139	3
	8,220	9,653
Revenue from other sources	-	48
Other operating revenue	-	48
Total revenue from operations	8,220	9,701

Geographical revenue is allocated based on the location of the customers.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

17.4 Changes in contract liabilities:

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Balance at the beginning of the year	439	344
Add:- Increase due to invoicing during the year	268	162
Less:- Amount recognised as revenue/other adjustments during the year	(260)	(67)
Balance at the end of the year	447	439
Expected revenue Recognition from remaining performance obligations:		
- within one year	38	30
- More than one year	409	408
	447	439

17.5 Contract balances

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Trade receivables (including unbilled revenue)	6,286	6,518
Contract liabilities	449	439

Trade receivables are non-interest bearing.

Contract liabilities include deferred revenue and advance from customers.

17.5 Performance obligation:

In relation to information about Company's performance obligations in contracts with customers [refer note 2(i)]. The Invoices are issued/generated according to contractual terms/ at the point in time and are usually payable within 60 to 120 days.

17.7 Significant customer

There are three (March 31, 2025: two) customers (one of which is wholly owned subsidiaries of the Company) who contribute individually more than 10% of the total revenue of the Company for the year ended March 31, 2026. Total revenue from such customers amounted to Rs. 6,224 (March 31, 2025: Rs 8,058).

18. Other income

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Interest income at amortised cost on:		
Deposits with banks and financial institutions	-	(0)
Others	4	1
Foreign exchange gain (net)	472	93
Net gain on sale of current investments	5	18
Net gain on financial assets measured at fair value through profit or loss	4	3
Other non-operating Income	7	9
	492	124

19. Cost of materials consumed

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Inventory at the beginning of the year	1,477	762
Add: Purchases	3,966	5,683
Less: Inventory at the end of the year	(1,169)	(1,477)
Cost of materials consumed	4,274	4,967

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

20. Changes in inventories of stock-in-trade, finished goods and work-in-progress

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Inventory at the beginning of the year		
Finished goods and Stock- in- trade	460	304
Work-in-progress	725	189
	1,185	494
Inventory at the end of the year		
Finished goods and Stock- in- trade	289	460
Work-in-progress	1,389	725
	1,678	1,185
	(493)	(692)

21. Employee benefits expense

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Salaries, wages and bonus *	736	700
Contribution to provident and other funds	38	29
Gratuity [Refer Note 27]	13	8
Employee stock compensation expense [Refer Note 34]	26	35
Staff welfare expenses	21	19
	834	792

*Includes expenses towards compensated absences [refer note 27]

22. Finance cost

Interest on lease liabilities [Refer Note 30]

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Interest expense on financial liability measured at amortised cost	39	-
Interest on lease liabilities [Refer Note 30]	4	7
	43	7

23. Depreciation and amortisation expense

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Depreciation of Property, plant and equipment [Refer Note 3]	330	320
Amortisation of intangible assets [Refer Note 4 (b)]	22	24
Depreciation of right-of-use-assets [Refer Note 4 (a)]	14	18
	366	361

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

24. Other expenses

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Communication expenses	1	1
Travelling and conveyance	26	32
Professional charges [Refer note (a) below]	531	313
Power and fuel	94	90
Insurance	18	12
Rates, taxes and fees	143	84
Repairs and maintenance		
Plant and machinery	62	62
Buildings	20	20
Others	77	14
Selling expenses		
Freight outwards and clearing charges	29	21
Sales promotion expense	0	1
Profit Share Expense	19	26
Provision/(reversal) for doubtful debts and Advances	169	(83)
Lab consumables	146	288
Research and development expenses [Refer note (b) below]	1,479	1,385
CSR expenditure [refer note 40]	13	13
Printing and stationery	3	2
Miscellaneous expenses	6	6
	2,836	2,287
(a) Payments to auditors:		
As auditor:		
Statutory audit fee	2	2
Tax Audit fee	1	1
In other capacity:		
Other services (certification fees)	—*	—*
Reimbursement of out-of-pocket expenses	—*	—*
	3	3
*Amounts are not presented since the amounts are rounded off to Rupees million.		
(b) Research and development expenses		
Research and development expenses	1,479	1,385
Other Research and development expenses included in other heads of account:		
Salaries, wages and bonus	398	361
Contribution to provident and other funds	23	19
Employee stock compensation expense	-	4
Staff welfare expenses	6	3
Lab consumables	146	288
	2,053	2,059

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

25. Related Party Disclosures:

The following table provides the value of transactions that have been entered into with related parties for the relevant financial year:

Sl No	Name of related party	Relationship	Description	For the year ended March 31, 2026 Expenses / (Income) / Other Transaction	March 31, 2026 Payables/ (Receivables)	For the year ended March 31, 2025 Expenses / (Income) / Other Transaction	March 31, 2025 Payables/ (Receivables)
1	Biocon Limited	Holding Company	Cross charges towards other expenses	113	-	94	-
			Reimbursement of incentive from government PLI	-	-	(80)	-
			Trade and other payables	-	2,176	-	2,085
			Power and facility charges recovered	162	-	190	-
			Purchase of goods	3,958	-	3,999	-
			Payment for leases	18	-	17	-
			Share based payments	26	-	52	-
2	Biocon Biosphere Limited	Fellow subsidiary	Trade and other payables	-	0	-	-
			Trade receivables	-	(113)	-	(4)
			Reimbursement of expenses	(109)	-	(4)	-
3	Biocon Pharma Ireland	Subsidiary	Trade and other payables	-	(0)	-	(2)
			Reimbursement of expenses	-	-	(0)	-
4	Biocon Pharma UK	Subsidiary	Reimbursement of expenses	149	-	84	-
			Trade receivables	-	(195)	-	(178)
			Trade and other payables	-	148	-	132
			Sale of Goods	(198)	-	(162)	-
5	Biocon Pharma Inc.	Subsidiary	Sale of goods	(3,344)	-	(6,445)	-
			Trade receivables	-	(3,702)	-	(4,837)
			Trade and other payables	-	894	-	806
			Cross charges towards other expenses	-	-	1	-
6	Biocon Pharma Malta Limited	Subsidiary	Trade and other payables	-	2	-	-
			Reimbursement of expenses	4	-	1	-
7	Biocon Pharma Malta I Limited	Subsidiary	Trade and other payables	-	58	-	57
			Trade receivables	-	(165)	-	(97)
			Sale of goods	(371)	-	(74)	-
			Reimbursement of expenses	234	-	106	-
8	Biocon Generics Inc	Subsidiary	Loans	-	-	-	-
			Interest on others	-	-	(1)	-
			Reimbursement of expenses	32	-	-	-
			Sale of goods	(17)	-	(1)	-
			Trade and other payables	-	-	-	(24)
			Trade receivables	-	(11)	-	(20)

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Sl No	Name of related party	Relationship	Description	For the year ended March 31, 2026 Expenses / (Income) / Other Transaction	March 31, 2026 Payables/ (Receivables)	For the year ended March 31, 2025 Expenses / (Income) / Other Transaction	March 31, 2025 Payables/ (Receivables)
9	Biocon FZ LLC	Fellow subsidiary	Sale of goods Trade receivables Trade and other payables	- - -	- - 2	(7) - -	- (5) 2
10	Syngene International Limited	Fellow subsidiary	Cross charges towards other expenses Trade receivables Trade and other payables	7 - -	- - 6	36 - -	- - 15
11	Biocon Biologics Limited	Fellow subsidiary	Cross charges towards other expenses Purchase of goods Trade receivables Trade and other payables	387 - - -	- - (98) 281	652 - - -	- - (98) 955
12	Biosimilar Collaborations Ireland Limited	Fellow subsidiary	Profit Shares Expense Trade receivables	(27) -	- (27)	- -	- -
13	Biocon Foundation	Fellow subsidiary	CSR Expenses Trade and other payables	13 -	- -	13 -	- -
(a) The Company has entered into service agreement with Biocon SEZ Developer and Biocon SEZ operating units of Biocon Limited for availing Land on lease and certain other facilities and services.							

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

(b) Key managerial personnel

Kiran Mazumdar Shaw	Director
Siddharth Mittal	Whole time Director (upto March 31, 2026)
Muralikrishnan KN	Director (upto March 31, 2026)
Shreehas Tambe	Additional Director (Non-executive Non- Independent) (w.e.f April 01, 2026)
Kedar Narayan	Additional Director (Non-executive Non- Independent) (w.e.f April 01, 2026)
Soudabi Neduvanchery	Chief Financial Officer (upto March 31, 2026)
Neel Kanth Chandgothia	Chief Financial Officer (w.e.f April 01, 2026)
Mayank Verma	Company Secretary (upto April 14, 2025)
Daksh Arora	Company Secretary (from May 08, 2025 to November 28, 2025)
Bhupendra Kumar Gupta	Company Secretary (from February 12, 2026 to March 27, 2026)
Anil Kumar Panchariya	Company Secretary (w.e.f March 28, 2026)
Rhonda Duffy	Manager (w.e.f April 01, 2026)

Fellow subsidiaries/subsidiaries companies with whom the Company did not have any transactions:

- | | |
|--|--|
| <ul style="list-style-type: none"> (i) Biocon Academy, a subsidiary of Biocon Limited (ii) Biocon SA, a subsidiary of Biocon Limited (iii) Biocon SDN BHD, a step down subsidiary of Biocon Limited (iv) Biocon Biologics Healthcare Sdn Bhd, a step down subsidiary of Biocon Limited (v) Biocon Biologics UK Limited, a step down subsidiary of Biocon Limited (vi) Biosimilars Newco Limited, a step down subsidiary of Biocon Limited (vii) Biocon Biologics Inc, a step down subsidiary of Biocon Limited (viii) Biocon Biologics Do Brasil Ltda, a step down subsidiary of Biocon Limited (ix) Biocon Biologics FZ LLC, a step down subsidiary of Biocon Limited (x) Biosimilars Collaborations Ireland Limited, a step down subsidiary of Biocon Limited (xi) Biocon Biologics Canada Inc , a step down subsidiary of Biocon Limited (xii) Biocon Biologics Germany GmbH, a step down subsidiary of Biocon Limited (xiii) Biocon Biologics France S.A.S, a step down subsidiary of Biocon Limited (xiv) Biocon Biologics Spain, S.L. , a step down subsidiary of Biocon Limited | <ul style="list-style-type: none"> (xv) Biocon Biologics Switzerland AG , a step down subsidiary of Biocon Limited (xvi) Biocon Biologics Belgium BV , a step down subsidiary of Biocon Limited (xvii) Biocon Biologics Finland OY , a step down subsidiary of Biocon Limited (xviii) Biocon Biologics Morocco S.A.R.L.A.U , a step down subsidiary of Biocon Limited (xix) Biocon Biologics Greece SINGLE MEMBER P.C , a step down subsidiary of Biocon Limited (xx) Biocon Biologics South Africa (PTY) Ltd , a step down subsidiary of Biocon Limited (xxi) Biocon Biologics (Thailand) Co. Ltd , a step down subsidiary of Biocon Limited (xxii) Biocon Biologics Philippines Inc , a step down subsidiary of Biocon Limited (xxiii) Biocon Biologics Italy S.R.L , a step down subsidiary of Biocon Limited (xxiv) Biocon Biologics Croatia LLC, a step down subsidiary of Biocon Limited (xxv) Biocon Biologics Global PLC, a step down subsidiary of Biocon Limited (xxvi) Syngene Scientific Solutions Limited, a step down subsidiary of Biocon Limited (xxvii) Syngene Manufacturing Solutions Limited, a step down subsidiary of Biocon Limited (xxviii) Syngene USA Inc., a step down subsidiary of Biocon Limited |
|--|--|
- (d) All transactions with these related parties are priced on an arm's length basis and none of the balances are secured.
- (e) The above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures".
- (f) The loans from holding company is presented net of repayments due to multiple transactions. Loans taken includes loan subsequently converted into preference shares. The loan taken from holding company are for Business purposes and interest rates are at arm's length. The Loans are payables on demand.

* Amounts are not presented since the amounts are rounded off to Rupees million.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

26. Tax expense

Particulars	March 31,2026	March 31,2025
(a) Amount recognised in Statement of profit and loss		
Current tax	-	160
Deferred tax expense / (income) related to:		
Origination and reversal of temporary differences	(288)	176
MAT credit entitlement	-	(155)
Tax expense for the year	(288)	181
(b) Reconciliation of effective tax rate		
Profit/(loss) before tax	(1,117)	1,004
Tax at statutory income tax rate 34.99% (March 31, 2025- 34.99%)	(391)	351
Tax effects of amounts which are not deductible / (taxable) in calculating taxable income		
Tax effect on brought losses set off against profits	-	(348)
Tax effect on non-creation of deferred tax due to tax holiday	-	174
Tax effect on current year losses	177	-
Others	(78)	3
Income tax expense	(292)	181

26. (d) Recognized deferred tax assets and liabilities

The following is the movement of deferred tax assets/liabilities presented in the balance sheet:

For the year ended March 31, 2026	Opening Balance	Recognized in profit or loss	Recognized in OCI	Closing Balance
Deferred tax liability				
Property, plant and equipment and intangible assets	184	(4)	-	181
Other Adjustment	-	-	-	-
Gross deferred tax liability	184	(4)	-	181
Deferred tax assets				
Defined Benefit Obligation	13	6	1	20
Losses available for offsetting against future taxable differences	-	177	-	177
MAT credit entitlement	372	35	-	407
Derivative liability	-	-	-	-
Other disallowable expenses	2	-	-	2
Other assets	76	66	-	142
Gross deferred tax assets	463	284	1	748
Net deferred tax (liability)/ asset	279	288	1	568

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

For the year ended March 31, 2025	Opening Balance	Recognized in profit or loss	Recognized in OCI	Closing Balance
Deferred tax liability				
Property, plant and equipment and intangible assets	193	(9)	-	184
Derivative assets	-	-	-	-
Other adjustment	(8)	8	-	-
Gross deferred tax liability	185	(1)	-	184
Deferred tax assets				
Defined Benefit Obligation	11	1	1	13
Losses available for offsetting against future taxable differences	164	(164)	-	-
MAT credit entitlement	217	155	-	372
Derivative liability	-	-	(0)	(0)
Other disallowable expenses	2	-	-	2
Other assets	90	(14)	-	76
Gross deferred tax assets	484	(22)	1	463
Net deferred tax (liability)/ asset	299	(21)	1	279

* Amounts are not presented since the amounts are rounded off to Rupees million.

(a) Deferred tax on convertible preference shares adjusted with equity component of OCRPS and accordingly deferred tax on carry forwarded losses reversed.

27. Employee benefit plans

- (i) The Company has a defined benefit gratuity plan as per the Payment of Gratuity Act, 1972. Under the act, employees who has completed five years of service is entitled to specific benefit. The level of benefit provided depends on the employee's length of service and salary at retirement/ termination age. The gratuity plan is unfunded.

The cost of the defined benefit plans and other long term benefits are determined using actuarial valuations. Actuarial valuations involve making various assumptions that may differ from actual developments in the future. These includes the determination of the discount rate, future salary increases and mortality rate. Due to these complexity involved in the valuation it is highly sensitive to the changes in these assumptions. All assumptions are reviewed at reporting date. The present value of the defined benefit obligation and the related current service cost and planned service cost were measured using the projected unit cost method.

The following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at balance sheet date:

Particulars	Present value of defined benefit obligation	Net defined benefit (asset)/liability
Balance as on April 01, 2025	38	38
Current service cost	8	8
Interest expense / (income)	5	5
Past service cost	20	20
Amount recognised in Statement of profit and loss	33	33
Remeasurements:		
Actuarial (gain) / loss arising from:		
Demographic assumptions	.*	-
Financial assumptions	(1)	(1)
Experience adjustment	7	7
Amount recognised in other comprehensive income	6	6
Employers contribution	-	-
Benefits paid	(5)	(5)
Balance as at March 31, 2026	72	72

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Particulars	Defined benefit obligation	Net defined benefit (asset) liability
Balance as on April 01, 2024	30	30
Current service cost	6	6
Interest expense / (income)	2	2
Amount recognised in Statement of profit and loss	8	8
Remeasurements:		
Actuarial (gain) / loss arising from:		
Demographic assumptions	~*	-
Financial assumptions	1	1
Experience adjustment	3	3
Amount recognised in other comprehensive income	4	4
Employers contribution	-	-
Benefits paid	(4)	(4)
(Liability transferred out)	-	-
Balance as at March 31, 2024	38	38

	March 31, 2026	March 31, 2025
Non-current	64	34
Current	8	4
	72	38

The Company pursuant to Karnataka Compulsory Gratuity Rules, 2024 (Gratuity Rules) has amended its Gratuity trust for compliance with Gratuity Rules, Income Tax Act, 1961 and other laws, as applicable. The amended Gratuity trust in compliance with the above rules is approved by Board of Directors of the Company in its meeting dated April 24, 2024 and under process of filing with the Commissioner of Income tax for approval. Accordingly, the Company expects to contribute its obligation under the Gratuity scheme pursuant to receipt of this approval.

* Amounts are not presented since the amounts are rounded off to Rupees million.

(ii) The assumptions used for gratuity valuation are as below:

	March 31, 2026	March 31, 2025
Interest rate	6.8%	6.6%
Discount rate	6.8%	6.6%
Expected return on plan assets	6.8%	6.6%
Salary increase	9.0%	9.0%
Attrition rate	14% - 30%	14% - 30%
Retirement age - Years	58	58

Assumptions regarding future mortality experience are set in accordance with published statistics and mortality tables as per IALM (2012-14).

The weighted average duration of the defined benefit obligation was 31 March 2026 - 6 years (March 31, 2025 - 6 years).

The defined benefit plan exposes the Company to actuarial risks, such as longevity and interest rate risk.

(iii) Sensitivity analysis

Sensitivity analysis is performed by varying a single parameter while keeping all the other parameters unchanged. Sensitivity analysis does not recognise the interrelationship between underlying parameters. Hence, the results may vary if two or more variables are changed simultaneously. The method used does not indicate anything about the likelihood of change in any parameter and the extent of the change if any. The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions are as below:

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

Particulars	March 31, 2026		March 31, 2025	
	Increase	Decrease	Increase	Decrease
Discount rate (1% movement)	(4)	4	(2)	2
Salary increase (1% movement)	4	(4)	2	(2)
Attrition rate (1% movement)	(1)	1	(1)	1

Sensitivity of significant actuarial assumptions is computed by varying one actuarial assumption used for the valuation of defined benefit obligation by one percentage, keeping all other actuarial assumptions constant. Although the analysis does not take account of the full distribution of cash flows expected under the plan, it does provide an approximation of the sensitivity of the assumption shown.

Maturity profile of defined benefit obligation

Particulars	March 31, 2026	March 31, 2025
1st Following year	8	4
2nd Following year	8	4
3rd Following year	11	4
4th Following year	7	5
5th Following year	7	4
Years 6 to 10	33	17
Years 11 and above	38	21

(iv) Risk Exposure:

These defined benefit plans typically expose the Company to actuarial risks as under:

- Investment Risk: The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds.
- Interest rate risk: A decrease in bond interest rate will increase the plan liability.
- Longevity risk: The present value of the defined plan liability is calculated by reference to the best estimate of the mortality of plan participants. An increase in the life expectancy will increase the plan's liability.
- Salary risk: Higher than expected increase in salary will increase the defined benefit obligation.

(v) Other Long term benefits

Present value of other long term benefits (i.e compensated absences) obligations at the end of the year :

Particulars	March 31, 2026	March 31, 2025
Compensated absences	47	40

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

28. Financial Instruments: Fair value and risk managements

A. Accounting classification and fair values

March 31, 2026	Carrying amount				Fair value			
	FVTPL #	FVTOCI	Amotised Cost	Total	Level 1	Level 2	Level 3 #	Total
Financial assets								
Non-current investments	-	-	2,069 *	2,069	-	-	-	-
Current investment	1,157	-	-	1,157	1,157	-	-	1,157
Loan	-	-	-	-	-	-	-	-
Derivative assets	-	-	-	-	-	-	-	-
Trade Receivables	-	-	6,286	6,286	-	-	-	-
Cash and cash equivalents and Other bank balances	-	-	304	304	-	-	-	-
Other financial assets	-	-	103	103	-	-	-	-
	1,157	-	8,762	9,919	1,157	-	-	1,157
Financial liabilities								
Borrowings	10,862	-	-	10,862	-	-	8,862#	8,862
Trade payables	-	-	4,881	4,881	-	-	-	-
Lease liabilities	-	-	36	36	-	-	-	-
Other financial liabilities	-	-	147	147	-	-	-	-
	10,862	-	5,064	15,926	-	-	8,862	8,862

March 31, 2025	Carrying amount				Fair value			
	FVTPL #	FVTOCI	Amotised Cost	Total	Level 1	Level 2	Level 3 #	Total
Financial assets								
Non-current investments	-	-	2,069*	2,069	-	-	-	-
Trade Receivables	-	-	6,518	6,518	-	-	-	-
Cash and cash equivalents and Other bank balances	-	-	218	218	-	-	-	-
Other financial assets	-	-	54	54	-	-	-	-
	-	-	8,859	8,859	-	-	-	-
Financial liabilities								
Borrowings	8,862	-	-	8,862	-	-	8,862#	8,862
Trade payables	-	-	5,608	5,608	-	-	-	-
Lease liabilities	-	-	50	50	-	-	-	-
Other financial liabilities	-	-	109	109	-	-	-	-
	8,862	-	5,767	14,629	-	-	8,862	8,862

- (a) The fair value of trade receivables, trade payables and other Current financial assets and liabilities is considered to be equal to the carrying amounts of these items due to their short – term nature
- (b) There have been no transfers between level 1, 2 and 3 needs to be made.
- (c) The Company enters into derivative financial instruments with various counterparties. Derivatives are valued using valuation techniques in consultation with market expert. The most frequently applied valuation technique include forward pricing, swap models and Black Scholes Merton Model (for options valuation), using present value calculations. The models incorporate various inputs including foreign exchange forward rates, interest rate curve and forward rates curve.

* Investment in equity shares and preference shares in subsidiaries has been accounted at cost as per Ind AS 27 "Separate Financial Statements".

These preference shares are convertible (variable number of equity shares), any time during the tenure of the instrument at the option of the holder. Owing to this feature, the instrument has been disclosed at its fair value which is equivalent to the face value.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

B. Measurement of fair values

Derivative financial instruments are valued based on quoted prices for similar assets and liabilities in active markets or inputs that are directly or indirectly observable in the market place.

For the fair values of forward contracts of foreign currencies, reasonably possible changes at the reporting date to one of the significant observable inputs, holding other inputs constant, would have the following effects in other comprehensive income (OCI)

Significant observable inputs	March 31, 2026 Impact on other equity		March 31, 2025 Impact on other equity	
	Increase	Decrease	Increase	Decrease
Spot rate of the foreign currency (1% movement)	-	-	-	-
Interest rates (100 bps movement)	-	-	-	-

Derivative financial instruments

The following table gives details in respect of outstanding foreign exchange forward and option contracts:

Particulars	(in Million)	
	March 31, 2026	March 31, 2025
Foreign exchange forward contracts to Sell	-	-

C. Significant Unobservable inputs used in Fair Values

As at March 31, 2026	Valuation Techniques	Fair value hierarchy	Significant unobservable inputs	Sensitivity of input to fair value measurement
a. Optionally Convertible Preference shares	Equivalent to face value	Level 3	Not Applicable	Not Applicable

As at March 31, 2025	Valuation Techniques	Fair value hierarchy	Significant unobservable inputs	Sensitivity of input to fair value measurement
a. Optionally Convertible Preference shares	Equivalent to face value	Level 3	Not Applicable	Not Applicable

D. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Credit risk
- Liquidity risk
- Market risk

(i) Risk management framework

The Company's risk management is carried out by the treasury department under policies approved by the Board of Directors. The Board provides written principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative and non-derivative financial instruments and investment of excess liquidity.

(ii) Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities and its financing activities, including deposits with banks and financial institutions and other financial instruments.

Customer credit risk is managed by each business unit subject to Company's established policy, procedures and control relating to customer credit risk management. The Audit and Risk Management Committee has established a credit policy under which each new customer is analysed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are offered. The Company's review includes external ratings, where available, and other publicly available financial information. Outstanding customer receivables are regularly monitored and any shipments to major customers are generally covered by letters of credit or other forms of credit insurance.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of trade and other receivables. The maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to Rs. 204 Million (March 31, 2025: Rs. 36 Million).

Allowance for Impairment	March 31, 2026	March 31, 2025
Opening balance	36	119
Impairment loss recognised	168	(83)
Impairment loss reversed/transferred	-	-
Closing balance	204	36

Refer note 9 for ageing of trade receivables.

Credit risk on cash and cash equivalent and derivatives is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies which are rated A1+ or AAA.

(iii) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company believes that the working capital is sufficient to meet its current requirements. Accordingly, no liquidity risk is perceived.

The following are the contractual maturities of financial liabilities and excluding interest payments. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay:

March 31, 2026

Particulars	Carrying amount	Less than 1 year	1 - 2 years	2-5 years	More than 5 years	Total
Borrowings	10,862	10,862	-	-	-	10,862
Trade payables	4,880	3,238	1,643	-	-	4,881
Lease Liabilities	36	18	16	10	-	44
Other current financial liabilities	147	147	-	-	-	147
Total	15,924	14,265	1,658	10	-	15,933

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of March 31, 2025:

March 31, 2025

Particulars	Carrying amount	Less than 1 year	1 - 2 years	2-5 years	More than 5 years	Total
Borrowings	8,862	8,862	-	-	-	8,862
Trade payables	5,608	5,360	248	-	-	5,608
Lease Liabilities	50	14	18	18	-	50
Other current financial liabilities	109	109	-	-	-	109
Total	14,629	14,345	266	18	-	14,628

(iv) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

The Company operates internationally and a major portion of the business is transacted in several currencies and consequently, the Company is exposed to foreign exchange risk through operating and borrowing activities in foreign currency. The Company holds derivative instruments such as foreign exchange forward, interest rate swaps to mitigate the risk of changes in exchange rates and foreign currency exposure.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

The currency profile of financial assets and financial liabilities as at March 31, 2026 and March 31, 2025 are as below:

March 31, 2026	USD	EUR	Others	Total
Financial assets				
Trade receivables	4,375	1,226	138	5,740
Cash and cash equivalents	215	-	-	215
Financial liabilities				
Trade payables	(924)	(22)	(65)	(1,012)
Net assets / (liabilities)	3,666	1,204	73	4,943
March 31, 2025	USD	EUR	Others	Total
Financial assets				
Trade receivables	6,034	123	174	6,331
Cash and cash equivalents	125	-	-	125
Financial liabilities				
Trade payables	(1,149)	(145)	(142)	(1,436)
Net assets / (liabilities)	5,010	(22)	32	5,020

Sensitivity analysis

The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments and the impact on other components of equity arises from foreign exchange forward/option contracts designated as cash flow hedges.

Particulars	Impact on profit or loss		Impact on other components of equity	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
USD Sensitivity				
INR/USD - Increase by 1%	37	50	37	50
INR/USD - Decrease by 1%	(37)	(50)	(37)	(50)
EUR Sensitivity				
INR/EUR - Increase by 1%	12	(0)	12	(0)
INR/EUR - Decrease by 1%	(12)	0	(12)	0
Others				
INR/EUR - Increase by 1%	—*	—*	—*	—*
INR/EUR - Decrease by 1%	—*	—*	—*	—*

*Amounts are not presented since the amounts are rounded off to Rupees million.

Derivative financial instruments

The Company uses derivative financial instruments exclusively for hedging financial risks that arise from its commercial business or financing activities. The Company's Treasury team manages its foreign currency risk by hedging forecasted transactions like sales, purchases and capital expenditures. When a derivative is entered for hedging, the Company matches the terms of those derivatives to the underlying exposure. All identified exposures are managed as per the policy duly approved by the Board of Directors.

29. Capital management

The key objective of the Company's capital management is to ensure that it maintains a stable capital structure with the focus on total equity to uphold investor, creditor, and customer confidence and to ensure future development of its business. The Company focused on keeping strong total equity base to ensure independence, security, as well as a high financial flexibility for potential future borrowings, if required without impacting the risk profile of the Company.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

The Company's goal is to continue to be able to return excess liquidity to shareholders by continuing to distribute annual dividends in future periods.

The amount of future dividends of equity shares will be balanced with efforts to continue to maintain an adequate liquidity status.

The capital structure as of March 31, 2026 and March 31, 2025 was as follows:

Particulars	March 31, 2026	March 31, 2025
Equity attributable to the equity shareholders of the Company	(70)	817
Equity and reserves	(70)	817
As a percentage of total capital	-0.6%	8.4%
Borrowings	-	-
Liability Component of OCRPS	10,862	8,862
Total borrowings	10,862	8,862
Debt Equity Ratio	1.01	0.92
Total capital (Equity and Borrowings)	10,792	9,679

30. Lease

The Company has entered into lease agreements for use of land and buildings which expires over a period ranging upto the year of 2027. Gross payments for the year aggregate to Rs. 18. (March 31, 2025: Rs. 25)

The followings is the movement in the lease liability :

Particulars	Land	Buildings	Total
Balance at the April 1, 2025	7	42	50
Addition during the year	-	-	-
Finance cost accrued during the year	1	4	4
Payment of lease liabilities	(4)	(14)	(18)
Balance at the March 31, 2026	4	32	36
Balance at the April 1, 2024	10	-	10
Addition during the year	-	57	57
Finance cost accrued during the year	1	6	7
Payment of lease liabilities	(4)	(21)	(25)
Balance at the March 31, 2025	7	42	50

The following is the breakup of current and non current lease liability

Particulars	March 31, 2026	March 31, 2025
Current lease liability	18	14
Non current lease liability	18	36
	36	50

The table below provides details regarding the contractual maturities of lease liabilities on an undiscounted basis:

Particulars	March 31, 2026	March 31, 2025
Less than one year	18	18
One to Five years	18	45
Total	36	63

The following are the amounts recognised in the statement of Profit or Loss for the year ended:

Particulars	March 31, 2026	March 31, 2025
Amortisation expenses on right of use-assets	14	18
Interest expenses on lease liabilities	4	7
Total	18	25

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

31. Corporate Social Responsibility

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities.

Particulars	In Cash	Yet to be paid in cash	Total
March 31, 2026			
(i) Construction/acquisition of any asset*	17	-	17
(ii) On purposes other than (i) above	-	-	-
	17	-	17
March 31, 2025			
(i) Construction/acquisition of any asset*	13	-	13
(ii) On purposes other than (i) above	-	-	-
	13	-	13

* Not owned by the Company.

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Amount required to be spent by the Company during the year:	13	13
Amount of expenditure incurred	17	13
Excess spent at the end of the year *	4	-
Total of previous years shortfall	-	-

* Excess spent will be carried forwarded and set-off in the subsequent financial year

Nature of CSR activities conducted by the company during year ended March 31, 2025 and March 31, 2024 are as follows:

- Promoting Education
- Mass Transit System
- Lake Rejuvenation

Refer Note 25 for details of related party transactions

32. Contingent liabilities and commitments

(i) Capital Commitments:

The estimated amount of contracts remaining to be executed on capital account and not provided for as at March 31, 2026, net of advances, is Rs. 58 (March 31, 2025:- Rs.29).

(ii) Contingent Liabilities:

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
(a) Claims against the Company not acknowledged as debt	9	-
The above includes:		
(i) Indirect taxation (includes matters pertaining to disputes on GST)	9	-

The Company has no contingent liability as at March 31, 2025 and March 31, 2024.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

33. Reconciliation of basic and diluted shares used in computing Earnings per share

Particulars	March 31, 2026	March 31, 2025
Earnings		
Profit/(Loss) for the year	(882)	823
Shares		
Basic outstanding shares	14,100,000	14,100,000
Add : Weighted average shares issued during the year	-	-
Weighted average shares used for computing basic and diluted EPS	14,100,000	14,100,000
Add: Effect of dilutive options granted but not yet exercised/not yet eligible for exercise-OCRPS	1,073,000,000	873,000,000
Weighted average shares used for computing diluted EPS	1,087,100,000	887,100,000
Earnings / (loss) per equity share		
Basic (in Rs)	(62.56)	58.38
Diluted (in Rs)	(62.56)	0.93

Diluted earnings per equity share is computed by dividing the net profit attributable to the owners of the Group by the weighted average number of equity shares considered for deriving basic earnings per equity share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares, except where the results would be anti-dilutive.

34. Employee stock compensation

The employees of the Company are eligible for shares under the Biocon Employee Stock Option Plan ('ESOP Plan 2000'), Biocon - Restricted Stock Units of Syngene International Limited ('RSU Plan 2015') and Biocon - Restricted Stock Units of Biocon Biologics India Limited ('RSU Plan 2019') (collectively "stock option plans") of Biocon Limited.

Total number of options outstanding	March 31, 2026	March 31, 2025
ESOP Plan 2000	22,500	74,250
RSU Plan 2019	-	81,965
RSU Plan 2020	-	17,320
RSU Plan 2025	250,000	250,000

The Company has recorded an amount of Rs. 26 (March 31, 2025: Rs. 35) as cost of the above stock option plans . The Company reimburses the cost to Biocon Limited.

35. Other Statutory Information

- The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property under Benami Transactions (Prohibition) Act, 1988 (45 of 1988)."
- The Company does not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.
- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- The Company is not declared as wilful defaulter by any bank or financial institution or government or any government authority.
- The Company does not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.
- The Company has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961
- The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.

- No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Group (Ultimate Beneficiaries). Further, The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Group shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Group ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries."

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

35. Ratio Analysis and its elements

Ratio	Numerator	Denominator	March 31,2025	March 31,2024	%change	Reason for variance
Current ratio	Current Assets	Current Liabilities	0.65	0.69	-5.48%	Decrease is due to increase in Borrowing during the current year.
Debt- Equity Ratio	Total Debt	Shareholder's Equity	(171.60)	10.85	-1682.00%	Optionally convertible redeemable non cumulative preference shares issuance to Biocon Limited
Debt Service Coverage ratio	Earnings for debt service = Net profit after taxes + Non-cash operating expenses+ Interest	Debt service = Interest & Lease Payments + Principal Repayments	(8.15)	45.82	-117.78%	Due to losses in current year resulting from decrease in revenue and increase in operating expenses
Return on Equity ratio	Net Profits after taxes – Preference Dividend	Average Shareholder's Equity	-236.16%	205.30%	-215.03%	Due to losses in current year resulting from decrease in revenue and increase in operating expenses
Trade Receivable Turnover Ratio	Net credit sales = Revenue from operations	Average Trade Receivable	1.28	1.68	-23.79%	
Trade Payable Turnover Ratio	Net credit purchases = Purchases of traded goods + Purchases of raw materials and packing materials + other expenses	Average Trade Payables	1.67	1.68	-0.57%	
Net Capital Turnover Ratio	Net sales = Total sales - sales return	Average Working capital = Current assets – Current liabilities	(1.56)	(1.93)	-19.16%	
Net Profit ratio	Net Profit after tax	Net sales = Total sales - sales return	-10.73%	8.49%	-226.45%	Due to losses in current year resulting from decrease in revenue and increase in operating expenses
Return on Capital Employed	Earnings before interest and taxes	Capital Employed = Tangible Net Worth (Total equity - Intangibles assets) + Total Borrowings - Deferred Tax Asset	-9.85%	11.22%	-187.73%	Increase in borrowing due to additional working capital loan
Return on Investment	Interest income on deposits + Net gain on mutual funds	Average Investment in deposits and mutual funds	0.86%	4.12%	-79.05%	Due to current year investments in mutual fund

38. Exceptional item

- (a) On November 21, 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Company assessed and disclosed the incremental impact of these changes on gratuity and compensated absences, particularly relating to the definition of "wages" considering the revised remuneration structure. The Company presented such incremental impact amounting to Rs. 20 primarily arising due to change in "wage" definition for the year ended March 31, 2026 under "Exceptional items". And associated tax impact of Rs. 4 is included in the tax expense for the year ended March 31, 2026.

Notes to financial statements

for the year ended March 31, 2026

(All amounts are in Indian Rupees Million, except share data and per share data, unless otherwise stated)

- (b) On December 6, 2025, the Biocon Limited (Holding Company) and Biocon Biologics Limited ('BBL') (Fellow subsidiary) announced a strategic corporate action to fully integrate the BBL as its wholly owned subsidiary. Pursuant to this strategic corporate action at the Biocon Group, the Company incurred expenses towards termination benefit payments for certain employees amounting to Rs 33. Considering the nature, significance, and non-recurring nature of these benefits, the related expenses have been disclosed as exceptional item.

39. There are no significant subsequent events that occurred after the reporting period till the date of these financial statements.

As per our report of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number.: 101248W/W-100022

Sanjay Sharma

Partner

Membership No.: 063980

Bengaluru

May 07, 2026

for **and on behalf of the Board of Directors of Biocon Pharma Limited**

Kiran Mazumdar-Shaw

Director

DIN: 00347229

Neel Kanth Chandgothia

Chief Financial Officer

Bengaluru

May 07, 2026

Shreehas Pradeep Tambe

Director

DIN: 09796480

Anil Kumar Panchariya

Company Secretary

Membership No.: F10956